U.S. government to purchase 100M doses of Moderna’s mRNA-1273 vaccine
Author : Saipriya Iyer | Published Date : 2020-08-13
U.S. President Donald Trump has recently announced that the government will purchase 100 million doses of the experimental COVID-19 vaccine developed by Moderna. The vaccine is currently at the advanced stage of development.
In a separate statement made by the biotechnology company, its mRNA-1273 vaccine is reportedly worth over $1.53 billion. The company is also planning to offer the federal government an option to purchase additional doses of over 400 million. The country has initially invested $955 million for the development of this vaccine, bringing its total investment to nearly $2.48 billion.
The mRNA-1273 vaccine has reached the late-stage, human trials. In this human trial phase, the company will examine the safety and efficacy of the vaccine in 30,000 subjects or volunteers. It anticipates obtaining the results as early as October 2020. In addition to Moderna, the U.S. government also has signed deals with other vaccine developers such as Johnson & Johnson, and Pfizer.
Trump has reportedly stated that the country has invested in the top 6 vaccine candidates for their effective development and rapid delivery to date. He further added that the military is set to accelerate the vaccine delivery once it is fully approved for use by the U.S. FDA.
Furthermore, the U.S. Department of HHS (Health & Human Services) had previously announced its plan to invest $1.95 billion in BioNTech and Pfizer to produce 100 million vaccine doses, with the option to obtain additional 500 million doses. HHS also announced that it would invest $1 billion in J&J for 100 million vaccine doses, with the option to gain an additional 200 million doses.
The vaccine agreements signed between several companies and the U.S. government are part of its efforts to accelerate the distribution, manufacturing, and development of vaccines against the coronavirus, under the ‘Operation Warp Speed’ program.
Stephane Bancel, CEO of Moderna, has stated that the company would price the vaccine ‘well-below value’ during the pandemic and price up at the market value once the virus is contained.
Source credit:
About Author
Saipriya Iyer . .
Saipriya Iyer presently works as a content developer for fractovia.org. Having dabbled with the domain of content creation for nearly half a decade, she now boasts of an enviable portfolio, holding substantial experience in penning down pieces related to technology, finance, and a wide spectrum of other industry verticals. A qualified computer engineering graduate from the University of Pune, Saipriya can often be found leveraging her knowledge of software technology and electronics in her write-ups. She can be contacted at- [email protected] | https://twitter.com/saipriya_i
Related News
Hero MotoCorp under investigation by Ministry of Corporate Affairs
The Indian Ministry of Corporate Affairs has reportedly ordered a probe into Hero MotoCorp to examine its association with an external vendor regarding alleged fund diversion. The objective of the investigation, conducted in the "public interest," is to evaluate the Hero MotoCorp owners... Read More>>
UK: Residents receive bills of up to £49,000 after Ovo acquires SSE
Customers of Ovo, the energy supplier were reportedly left shocked when they received energy bills of up to £49,000, due to data errors that led to overinflated energy bills for some residents. Ovo accepted that some of its customers have been affected by erroneous meter readings, and it bl... Read More>>
Bob Iger returns to Disney as CEO less than a year post retirement
Bob Iger, the ex-CEO of Walt Disney Co., is reportedly coming back to the mass media giant less than a year after his retirement. The surprise announcement comes at a time when Disney is struggling to earn profits from its streaming TV services. According to a statement released by Disney late Su... Read More>>